Torley Helen sold $1.1M of HALO
Torley Helen (PRESIDENT AND CEO) sold 16,600 shares of HALOZYME THERAPEUTICS, INC. (HALO) at $66.31 ($1.10M total) on 2026-06-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The market may briefly reassess sentiment around management’s outlook, but the pre-arranged nature usually limits inference about new negative fundamentals.
Market read
A disclosed CEO sale at a specific price/value; likely low incremental trading impact absent additional corroborating news.
What to watch
The filing doesn’t indicate whether other insiders/funds are selling or buying; without follow-on transactions, the signal may be overstated.
Background
This is an SEC Form 4 insider transaction disclosure for HALO’s CEO (Torley Helen) showing an open-market sale executed under a pre-arranged Rule 10b5-1 plan.
Ticker impact
HALO’s CEO sold 16,600 shares in an open-market transaction disclosed via SEC Form 4 on June 2 under a 10b5-1 plan.
Likely limited near-term impact; any reaction would be modest and fade unless follow-on selling accelerates.
The filing provides a specific sale price/value and confirms a pre-arranged 10b5-1 plan, reducing the likelihood of immediate negative information content.
Market effects
Minimal—single-company insider transaction without new clinical/regulatory or deal information.
None.
None.
Counterpoint
Even with a 10b5-1 plan, repeated or large CEO sales can still pressure sentiment if investors interpret it as reduced confidence.
Key entities
- issuerHALOZYME THERAPEUTICS, INC.
Subject of the insider transaction disclosure; CEO sold shares via open-market sale under a 10b5-1 plan.
- insiderTorley Helen
President and CEO who sold 16,600 shares at $66.3140 on 2026-06-02.
